Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Expands Board and Announces Annual Meeting Results
Summary
Alnylam Pharmaceuticals, Inc. expanded its Board of Directors from ten to eleven members, electing Dr. Benjamin F. Cravatt as a Class III director. The Annual Meeting of Stockholders saw the re-election of three Class I directors, approval of executive compensation in a non-binding vote, and ratification of PricewaterhouseCoopers LLP as the independent auditors for the fiscal year ending December 31, 2026. Dr. Cravatt will receive an annual cash retainer and equity awards as part of his compensation.
Profitelligence Alerts
Get alerts for ALNY
Be first to know when Alnylam Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.
Official SEC Documents
Advertisement